Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. / Kielgast, Urd; Krarup, Thure; Holst, Jens Juul; Madsbad, Sten; Krarup, Thure.

In: Diabetes Care, Vol. 34, No. 7, 07.2011, p. 1463-1468.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kielgast, U, Krarup, T, Holst, JJ, Madsbad, S & Krarup, T 2011, 'Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function', Diabetes Care, vol. 34, no. 7, pp. 1463-1468. https://doi.org/10.2337/dc11-0096

APA

Kielgast, U., Krarup, T., Holst, J. J., Madsbad, S., & Krarup, T. (2011). Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care, 34(7), 1463-1468. https://doi.org/10.2337/dc11-0096

Vancouver

Kielgast U, Krarup T, Holst JJ, Madsbad S, Krarup T. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011 Jul;34(7):1463-1468. https://doi.org/10.2337/dc11-0096

Author

Kielgast, Urd ; Krarup, Thure ; Holst, Jens Juul ; Madsbad, Sten ; Krarup, Thure. / Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. In: Diabetes Care. 2011 ; Vol. 34, No. 7. pp. 1463-1468.

Bibtex

@article{36a1b69dacc64154a9bb18f0d4c168c6,
title = "Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function",
abstract = "OBJECTIVE To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual {\ss}-cell function. RESEARCH DESIGN AND METHODS Ten type 1 diabetic patients with residual {\ss}-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied. All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy. Continuous glucose monitoring with identical food intake and physical activity was performed before (week 0) and during (week 4) treatment. Differences in insulin dose; HbA(1c); time spent with blood glucose <3.9, >10, and 3.9-9.9 mmol/L; and body weight were evaluated. RESULTS Insulin dose decreased from 0.50 ± 0.06 to 0.31 ± 0.08 units/kg per day (P < 0.001) in C-peptide-positive patients and from 0.72 ± 0.08 to 0.59 ± 0.06 units/kg per day (P < 0.01) in C-peptide-negative patients treated with liraglutide but did not change with insulin monotherapy. HbA(1c) decreased in both liraglutide-treated groups. The percent reduction in daily insulin dose was positively correlated with {\ss}-cell function at baseline, and two patients discontinued insulin treatment. In C-peptide-positive patients, time spent with blood glucose <3.9 mmol/L decreased from 3.0 to 1.0 h (P = 0.03). A total of 18 of 19 patients treated with liraglutide lost weight during treatment (mean [range] -2.3 ± 0.3 kg [-0.5 to -5.1]; P < 0.001). Transient gastrointestinal adverse effects occurred in almost all patients treated with liraglutide. CONCLUSIONS Treatment with liraglutide in type 1 diabetic patients reduces insulin dose with improved or unaltered glycemic control.",
keywords = "Adolescent, Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Exercise Test, Female, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Insulin, Insulin-Secreting Cells, Male, Middle Aged, Weight Loss",
author = "Urd Kielgast and Thure Krarup and Holst, {Jens Juul} and Sten Madsbad and Thure Krarup",
year = "2011",
month = jul,
doi = "10.2337/dc11-0096",
language = "English",
volume = "34",
pages = "1463--1468",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "7",

}

RIS

TY - JOUR

T1 - Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

AU - Kielgast, Urd

AU - Krarup, Thure

AU - Holst, Jens Juul

AU - Madsbad, Sten

AU - Krarup, Thure

PY - 2011/7

Y1 - 2011/7

N2 - OBJECTIVE To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual ß-cell function. RESEARCH DESIGN AND METHODS Ten type 1 diabetic patients with residual ß-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied. All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy. Continuous glucose monitoring with identical food intake and physical activity was performed before (week 0) and during (week 4) treatment. Differences in insulin dose; HbA(1c); time spent with blood glucose <3.9, >10, and 3.9-9.9 mmol/L; and body weight were evaluated. RESULTS Insulin dose decreased from 0.50 ± 0.06 to 0.31 ± 0.08 units/kg per day (P < 0.001) in C-peptide-positive patients and from 0.72 ± 0.08 to 0.59 ± 0.06 units/kg per day (P < 0.01) in C-peptide-negative patients treated with liraglutide but did not change with insulin monotherapy. HbA(1c) decreased in both liraglutide-treated groups. The percent reduction in daily insulin dose was positively correlated with ß-cell function at baseline, and two patients discontinued insulin treatment. In C-peptide-positive patients, time spent with blood glucose <3.9 mmol/L decreased from 3.0 to 1.0 h (P = 0.03). A total of 18 of 19 patients treated with liraglutide lost weight during treatment (mean [range] -2.3 ± 0.3 kg [-0.5 to -5.1]; P < 0.001). Transient gastrointestinal adverse effects occurred in almost all patients treated with liraglutide. CONCLUSIONS Treatment with liraglutide in type 1 diabetic patients reduces insulin dose with improved or unaltered glycemic control.

AB - OBJECTIVE To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual ß-cell function. RESEARCH DESIGN AND METHODS Ten type 1 diabetic patients with residual ß-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied. All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy. Continuous glucose monitoring with identical food intake and physical activity was performed before (week 0) and during (week 4) treatment. Differences in insulin dose; HbA(1c); time spent with blood glucose <3.9, >10, and 3.9-9.9 mmol/L; and body weight were evaluated. RESULTS Insulin dose decreased from 0.50 ± 0.06 to 0.31 ± 0.08 units/kg per day (P < 0.001) in C-peptide-positive patients and from 0.72 ± 0.08 to 0.59 ± 0.06 units/kg per day (P < 0.01) in C-peptide-negative patients treated with liraglutide but did not change with insulin monotherapy. HbA(1c) decreased in both liraglutide-treated groups. The percent reduction in daily insulin dose was positively correlated with ß-cell function at baseline, and two patients discontinued insulin treatment. In C-peptide-positive patients, time spent with blood glucose <3.9 mmol/L decreased from 3.0 to 1.0 h (P = 0.03). A total of 18 of 19 patients treated with liraglutide lost weight during treatment (mean [range] -2.3 ± 0.3 kg [-0.5 to -5.1]; P < 0.001). Transient gastrointestinal adverse effects occurred in almost all patients treated with liraglutide. CONCLUSIONS Treatment with liraglutide in type 1 diabetic patients reduces insulin dose with improved or unaltered glycemic control.

KW - Adolescent

KW - Adult

KW - Blood Glucose

KW - C-Peptide

KW - Diabetes Mellitus, Type 1

KW - Exercise Test

KW - Female

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin

KW - Insulin-Secreting Cells

KW - Male

KW - Middle Aged

KW - Weight Loss

U2 - 10.2337/dc11-0096

DO - 10.2337/dc11-0096

M3 - Journal article

C2 - 21593296

VL - 34

SP - 1463

EP - 1468

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 7

ER -

ID: 34068538